The Addario Lung Cancer Medical Institute (ALCMI) is patient-founded, international non-profit consortium that has established centralized translational infrastructures and coordinated research planning, all within a uniform contractual framework governing collaboration data, biospecimens, intellectual property and much more. ALCMI’s mission is to help transform lung cancer into a survivable disease via improved understanding of tumor biology, identifying and validating druggable targets, elucidating molecular bases for acquired drug resistance, and accelerated development/delivery of targeted therapies via early phase clinical trials.

To these ends, ALCMI is seeking results-focused collaborations with motivated researchers from academia, community centers, and the biopharmaceutical and molecular diagnostics industries:

•biobanking

•tumor biology

•molecular screening

•correlative sciences

•clinical trials

Please contact Steven Young at syoung@alcmi.net or 203-226-5765.